Navigation Links
InteKrin Therapeutics Presented Phase 2b Clinical Data at the 2010 American Diabetes Association Annual Meeting, Demonstrating Improved Glycemic Control in Patients with Type 2 Diabetes Without Causing the Edema Seen with Pioglitazone
Date:6/29/2010

sensitization is a core therapeutic mechanism for addressing the Type 2 Diabetes epidemic," added Dr. Linda Higgins, President & Chief Operating Officer of InteKrin Therapeutics. "INT131 besylate offers a potential significant advance in addressing the critical need for a safe insulin sensitizer."

About INT131:

INT131 is a next-generation insulin sensitizer that addresses insulin resistance, a key etiological feature in the onset and subsequent progression of Type 2 Diabetes. As a selective PPAR-gamma modulator (SPPARM), INT131 has been designed to provide potent glucose lowering and durability of effect without the recognized side effects of the currently available insulin sensitizers which, unlike INT131, are full PPAR-gamma agonists. InteKrin has completed an End-Of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for INT131 and is moving the program into Phase 3 development.

About InteKrin (www.InteKrin.com)

InteKrin Therapeutics is a privately-held clinical-stage drug development company focused on diabetes, obesity and metabolic disease. InteKrin's business strategy is to build a robust portfolio of high value products by in-licensing clinical-stage therapeutic candidates that address significant unmet medical needs and rapidly move them through critical development stages. InteKrin's team of world-class scientific and medical experts includes veterans from several successful BioPharma organizations, internationally recognized experts in nuclear receptors and metabolism, top scientists formerly with the Food and Drug Administration and key clini
'/>"/>

SOURCE InteKrin Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
2. InteKrin Therapeutics Announces Enrollment Completion of 360 Patient, 24 week Phase 2b Study
3. InteKrin Therapeutics to Present at the 2009 American Diabetes Association Annual Meeting
4. InteKrin Therapeutics Presents Positive Long Term INT131 Preclinical Cardiovascular Safety Data at the 45th Annual European Association for the Study of Diabetes Meeting
5. InteKrin Therapeutics Co-Founder Receives Appointment as Professor of Medicine at Harvard Medical School
6. InteKrin Therapeutics to Present Phase 2b Clinical Data for Edema at the 2010 American Diabetes Association Annual Meeting
7. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
8. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
11. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  In an unprecedented effort to curb the ... ambulances and other transport vehicles, an advanced and portable UV germicidal ... for the first time. In order to prevent ... deadly pathogens, West Palm Beach Fire Rescue ...
(Date:1/15/2014)... TORONTO , Jan. 15, 2014  According to ... medical technology market intelligence, the United ... occlusion (TEO) device markets will expand moderately through ... fastest-growing segments. In particular, increasing interest in drug-eluting ...
(Date:1/15/2014)... , Jan. 15, 2014 ... research report is available in its ... Markets and Technologies for Advanced Drug ... of Administration ...
Breaking Medicine Technology:Superbugs No Longer Ride In Rescue Vehicles 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
(Date:4/17/2014)... The presence of chronic inflammation in benign ... prostate cancer, and this association was found even ... according to a study published in Cancer ... the American Association for Cancer Research. , An ... participants of the placebo arm of the Prostate ...
(Date:4/17/2014)... to a study published today in PLOS Pathogens ... where malaria is common can mount an immune response ... to avoid repeated bouts of high fever and illness ... their bloodstream. The findings may help researchers develop future ... the malaria parasite. , Each year, approximately 200 million ...
(Date:4/17/2014)... Bonheur Children,s Hospital Pediatrician-in-Chief Jon McCullers, MD, was ... April issue of Nature Reviews Microbiology , ... Dr. McCullers, a world-renowned infectious disease specialist, and ... University of Tennessee Health Science Center, analyzed the ... 1957 and 1968 pandemics, as well as more ...
(Date:4/17/2014)... The cause of neuronal death in Parkinson,s disease is ... may be mistaken for foreign invaders and killed by ... autoimmune diseases like type I diabetes, celiac disease, and ... published April 16, 2014, in Nature Communications . ... in Parkinson,s disease; but if true, it could lead ...
(Date:4/17/2014)... team led by researchers at UC Davis has shown ... key role in cell division, also boosts the mitochondrial ... time the complex has been shown to perform both ... excellent target to control cellular energy production, potentially advancing ... online today in the journal Developmental Cell . ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Is Parkinson's an autoimmune disease? 2Health News:Dual role: Key cell division proteins also power up mitochondria 2
... ALTO, Calif., April 29 Varian Medical Systems (NYSE: ... continuing operations of $0.64 per diluted share in the ... from continuing operations of $0.57 per diluted share in ... instruments operation, net earnings per diluted share in the ...
... Varian, Inc. (NasdaqGS: VARI) today reported second quarter fiscal ... 17.2% from the second quarter of fiscal year 2008.Non-GAAP ... of 2009 were $0.55 (including $0.05 of share-based compensation ... $0.07 of share-based compensation expense) in the second quarter ...
... juice could slow prostate cancer , , WEDNESDAY, April 29 ... a citrus flavor, might help ward off painful calcium ... citrate, which is known to inhibit calcium formation, according ... be presented Sunday at the American Urological Association annual ...
... years, report warns , , WEDNESDAY, April 29 (HealthDay News) -- ... of new cancers over the next two decades, driven by ... new report predicts. , Rates of new cancer diagnosis ... generally and by 67 percent among people aged 65 or ...
... INDIANAPOLIS , April 29 /PRNewswire/ ... a good start. WellPoint is pleased that the ... underlying quality and cost issues within our health care ... programs and services private plans have pioneered. We also ...
... Nancy Pelosi spoke on the House floor this morning in strong ... The resolution passed the House by a vote of 233 to ... today. It does not require the signature of the President. Below ... indeed an honor to call Mr. Spratt a colleague. We say ...
Cached Medicine News:Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 2Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 3Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 4Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 5Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 6Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 7Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 8Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 9Health News:Varian, Inc. Reports Second Quarter 2009 Results 2Health News:Varian, Inc. Reports Second Quarter 2009 Results 3Health News:Varian, Inc. Reports Second Quarter 2009 Results 4Health News:Varian, Inc. Reports Second Quarter 2009 Results 5Health News:Varian, Inc. Reports Second Quarter 2009 Results 6Health News:Varian, Inc. Reports Second Quarter 2009 Results 7Health News:Varian, Inc. Reports Second Quarter 2009 Results 8Health News:Varian, Inc. Reports Second Quarter 2009 Results 9Health News:Varian, Inc. Reports Second Quarter 2009 Results 10Health News:Varian, Inc. Reports Second Quarter 2009 Results 11Health News:Varian, Inc. Reports Second Quarter 2009 Results 12Health News:Varian, Inc. Reports Second Quarter 2009 Results 13Health News:Varian, Inc. Reports Second Quarter 2009 Results 14Health News:Varian, Inc. Reports Second Quarter 2009 Results 15Health News:Varian, Inc. Reports Second Quarter 2009 Results 16Health News:Varian, Inc. Reports Second Quarter 2009 Results 17Health News:Varian, Inc. Reports Second Quarter 2009 Results 18Health News:Varian, Inc. Reports Second Quarter 2009 Results 19Health News:Varian, Inc. Reports Second Quarter 2009 Results 20Health News:Varian, Inc. Reports Second Quarter 2009 Results 21Health News:Varian, Inc. Reports Second Quarter 2009 Results 22Health News:Varian, Inc. Reports Second Quarter 2009 Results 23Health News:Some Diet Sodas May Ward Off Kidney Stones 2Health News:Some Diet Sodas May Ward Off Kidney Stones 3Health News:Minorities to Bear Brunt of Rise in U.S. Cancer Cases 2Health News:Minorities to Bear Brunt of Rise in U.S. Cancer Cases 3Health News:Pelosi: Budget is a Blueprint for the Future 2
Curved to the Left 9# with 30 cm long silicone tubing with connector; 40mm overall length; in stainless steel...
... Cordis biopsy forceps are designed for endomyocardial biopsies. ... consist of a 3-pull ring handle, stainless steel ... thumb ring rotates to accommodate any position. ,A ... closed. The jaws are opened by moving the ...
4-Strand Basket Retriever was developed to facilitate recovery of foreign objects from within the neuro, peripheral, and cardiovasculature, the In-Time Retrieval Device features an integrated corewir...
... non-invasive, virtually pain-free alternative to conventional open ... indications. With Leksell Gamma Knife C the ... improves the ability to mould the radiation ... allows a more selective irradiation and thus ...
Medicine Products: